Taysha Gene Therapies (NASDAQ:TSHA) Price Target Raised to $17.00
by Scott Moore · The Cerbat GemTaysha Gene Therapies (NASDAQ:TSHA – Free Report) had its target price upped by Canaccord Genuity Group from $14.00 to $17.00 in a report published on Monday morning,Benzinga reports. They currently have a buy rating on the stock.
Several other brokerages have also recently issued reports on TSHA. Raymond James Financial reaffirmed a “strong-buy” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Truist Financial raised Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Needham & Company LLC lifted their price objective on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $11.64.
Check Out Our Latest Stock Report on Taysha Gene Therapies
Taysha Gene Therapies Stock Down 0.4%
Taysha Gene Therapies stock opened at $4.55 on Monday. The company has a debt-to-equity ratio of 0.20, a current ratio of 12.23 and a quick ratio of 12.23. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $6.02. The company has a market cap of $1.31 billion, a PE ratio of -13.38 and a beta of 1.10. The stock’s 50 day moving average price is $4.54 and its 200 day moving average price is $4.67.
Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last issued its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. The firm had revenue of $5.49 million for the quarter, compared to analyst estimates of $1.89 million. On average, sell-side analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current fiscal year.
Insider Activity at Taysha Gene Therapies
In related news, CFO Kamran Alam sold 78,968 shares of the company’s stock in a transaction on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total value of $375,098.00. Following the completion of the transaction, the chief financial officer directly owned 1,467,635 shares in the company, valued at approximately $6,971,266.25. This represents a 5.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $4.71, for a total value of $942,000.00. Following the completion of the transaction, the insider owned 1,006,439 shares of the company’s stock, valued at $4,740,327.69. The trade was a 16.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Taysha Gene Therapies
Several institutional investors have recently added to or reduced their stakes in TSHA. AQR Capital Management LLC increased its stake in Taysha Gene Therapies by 325.6% in the first quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock valued at $150,000 after purchasing an additional 82,545 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Taysha Gene Therapies by 13.5% in the 2nd quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock worth $539,000 after purchasing an additional 27,794 shares during the period. Prudential Financial Inc. raised its holdings in shares of Taysha Gene Therapies by 50.5% in the 2nd quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock worth $53,000 after purchasing an additional 7,650 shares during the period. Invesco Ltd. lifted its stake in shares of Taysha Gene Therapies by 27.4% in the 2nd quarter. Invesco Ltd. now owns 203,671 shares of the company’s stock valued at $470,000 after purchasing an additional 43,772 shares in the last quarter. Finally, Marshall Wace LLP purchased a new stake in shares of Taysha Gene Therapies during the 2nd quarter worth about $184,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.
Taysha Gene Therapies Company Profile
Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.
Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.